SCHEMBL5536027

SCHEMBL5536027

COc1cccc(CNc2cc[c]cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.59
MAPT P10636 4/20 0.58
ALDH1A1 P00352 5/20 0.57
KDM4E B2RXH2 3/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
GAA P10253 2/20 0.57
ABCB1 P08183 1/20 0.52
ABCG2 Q9UNQ0 1/20 0.52
CHRM2 P08172 2/20 0.51
NOS1 P29475 1/20 0.50
MAOB P27338 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HTT P42858 1/20 0.48
MMP13 P45452 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CHRM1 P11229 1/20 0.47
CHRM3 P20309 1/20 0.47
NPC1 O15118 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1134085 0.85 HIF1A (0.76) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL30373777 0.85 HIF1A (0.76) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL5545073 0.85 HIF1A (0.55) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL24097464 0.83 MAPT (0.68) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL6695006 0.83 MAPT (0.68) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL30854961 0.81 HIF1A (0.59) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL2987758 0.81 HIF1A (0.63) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL25547419 0.81 HIF1A (0.63) HIF1AMAPTALDH1A1KDM4EMEN1
SCHEMBL5535976 0.81 KDM5A (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2185129 0.80 MAPT (0.65) HIF1AMAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HIF1A 2302/4885MAPT 4117/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.